Biomarkers
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.APOE4 genotype increases amyloid positivity risk in memory care patients. APOE4 carriers, especially females with APOE3/4, show higher amyloid burden, informing personalized dementia prevention and treatment.
Area Of Science
- Neuroscience
- Genetics
- Medical Imaging
Background
- Limited real-world data exists on APOE genotype utility in memory care.
- The IDEAS study assessed amyloid PET's clinical impact in Medicare beneficiaries with cognitive impairment.
- The ANGI study analyzed DNA from IDEAS participants to link genetics with amyloid status.
Purpose Of The Study
- To evaluate the predictive value of APOE genotype in determining amyloid status and burden.
- To assess APOE's role in real-world memory care settings.
- To investigate the relationship between APOE genotype and amyloid PET findings.
Main Methods
- Included 1637 Medicare beneficiaries from ANGI and IDEAS with cognitive impairment.
- Determined amyloid PET positivity using visual reads and a Centiloid threshold.
- Used logistic regression and ANCOVA to analyze odds of positivity and differences in amyloid burden (Centiloids), adjusting for covariates.
Main Results
- APOE4 carriers (heterozygotes and homozygotes) had higher dementia rates and lower MMSE scores.
- APOE4 genotypes (APOE2/4, APOE3/4, APOE4/4) showed a dose-dependent increase in odds of amyloid positivity.
- Females with APOE3/4 genotype had significantly higher odds of being amyloid-positive compared to males with APOE3/3 genotype.
Conclusions
- APOE genotype is a significant predictor of amyloid positivity and burden in real-world memory care.
- Genetic risk stratification, including sex-specific factors, can inform personalized dementia prevention and treatment strategies.
- Incorporating genetic information may lead to improved clinical outcomes in cognitive impairment management.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...